Status:
COMPLETED
A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine
Lead Sponsor:
Janssen Research & Development, LLC
Conditions:
Attention Deficit Disorder With Hyperactivity
Eligibility:
All Genders
Brief Summary
The purpose of this study is to estimate the observed incidence of the health outcomes (suicide attempt or ideation, suicide ideation, suicide attempt, psychosis, and substance abuse) in a cohort of p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- New users of methylphenidate monotherapy or lisdexamfetamine monotherapy or atomoxetine monotherapy or amphetamine/dextroamphetamine combo therapy
- Prior diagnosis of ADHD
Exclusion
Key Trial Info
Start Date :
October 9 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 25 2019
Estimated Enrollment :
430000 Patients enrolled
Trial Details
Trial ID
NCT04132557
Start Date
October 9 2019
End Date
October 25 2019
Last Update
June 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Janssen Investigative Site
Titusville, New Jersey, United States, 08560